Technology, Healthcare, Financials Jun 10, 2022 07:53 PM (GMT+8) · EqualOcean
Luoxin pharmaceutical announced that Shandong Luoxin, a subsidiary of the company, recently received the drug registration certificate of fosapitam meglumine for injection approved and issued by the State Drug Administration. The drug registration certificate of fosapitam meglumine for injection is deemed to have passed the consistency evaluation, which will improve the market competitiveness of the company in the field of anti-tumor and further enrich the company's product line.
Related companies: